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Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to treat or protect against global circulating viruses. Here we probed the neutralizing antibody repertoires of four human immunodeficiency virus (HIV)-infected donors with remarkably broad and potent neutralizing responses and rescued 17 new monoclonal antibodies that neutralize broadly across clades. Many of the new monoclonal antibodies are almost tenfold more potent than the recently described PG9, PG16 and VRC01 broadly neutralizing monoclonal antibodies and 100-fold more potent than the original prototype HIV broadly neutralizing monoclonal antibodies [1] [2] [3] . The monoclonal antibodies largely recapitulate the neutralization breadth found in the corresponding donor serum and many recognize novel epitopes on envelope (Env) glycoprotein gp120, illuminating new targets for vaccine design. Analysis of neutralization by the full complement of anti-HIV broadly neutralizing monoclonal antibodies now available reveals that certain combinations of antibodies should offer markedly more favourable coverage of the enormous diversity of global circulating viruses than others and these combinations might be sought in active or passive immunization regimes. Overall, the isolation of multiple HIV broadly neutralizing monoclonal antibodies from several donors that, in aggregate, provide broad coverage at low concentrations is a highly positive indicator for the eventual design of an effective antibody-based HIV vaccine.
Most successful antiviral vaccines elicit neutralizing antibodies as a correlate of protection 4, 5 . For highly variable viruses-such as HIV, hepatitis C virus (HCV) and, to a lesser extent, influenza-vaccine design efforts have been hampered by the difficulties associated with eliciting neutralizing antibodies that are effective against the enormous diversity of global circulating isolates (that is, broadly neutralizing antibodies) 6, 7 . However, for HIV for example, 10-30% of infected individuals do, in fact, develop broadly neutralizing sera and protective broadly neutralizing monoclonal antibodies have been isolated from infected donors 1, 2, [8] [9] [10] [11] [12] . It has been suggested that, given the appropriate immunogen, it should be possible to elicit these types of responses by vaccination 13 and understanding the properties of broadly neutralizing monoclonal antibodies has become a major goal in research on highly variable viruses.
We have previously screened sera from approximately 1,800 HIVinfected donors for neutralization breadth and potency, designating the top 1% as 'elite neutralizers', based on a score incorporating both breadth and potency 14 . In this study, we set out to isolate broadly neutralizing monoclonal antibodies from the top four elite neutralizers ( Supplementary Table 1 ) by screening antibody-containing memory B cell supernatants for broad neutralizing activity using a recently described high-throughput functional approach 2 . Antibody variable genes were rescued from B-cell cultures that showed cross-clade neutralizing activity and expressed as full-length IgGs. Analysis of the sequences revealed that all of the monoclonal antibodies isolated from each individual donor belong to a distant, but clonally related cluster of antibodies (Supplementary Table 2 ). Because it has been proposed that antibodies from HIV-infected patients are often polyreactive 15, 16 , we tested the new monoclonal antibodies for binding to a panel of antigens and showed that they were not polyreactive ( Supplementary Fig. 2 ).
The potency and breadth of the monoclonal antibodies were next assessed on a 162-pseudovirus panel representing all major circulating HIV subtypes ( Fig. 1 and Supplementary Tables 3 and 4) 2 . All of the monoclonal antibodies exhibited cross-clade neutralizing activity, but more strikingly, several showed exceptional potency. The median antibody concentrations required to inhibit HIV activity by 50% or 90% (IC 50 and IC 90 values), of PGT monoclonal antibodies 121-123 and 125-128 were almost tenfold lower (that is, more potent) than the recently described PG9, PG16, VRC01 and PGV04 broadly neutralizing monoclonal antibodies 1,2 (E. Falkowska et al., manuscript in preparation, X. Wu et al., Science, in the press), and approximately 100-fold lower than other broadly neutralizing monoclonal antibodies {Lists of authors and affiliations appear in Supplementary Information. 1 a, Median neutralization potency against viruses neutralized with an IC 50 , 50 mg ml 21 . b, Neutralization breadth at different IC 50 cut-offs. described earlier ( Fig. 1) . At concentrations less than 0.1 mg ml 21 , these monoclonal antibodies still neutralized 27% to 50% of viruses in the panel ( Fig. 1 ). Although PGT monoclonal antibodies 135, 136 and 137 showed a lesser neutralization breadth than the other monoclonal antibodies, they all still potently neutralized over 30% of the clade C viruses on the panel ( Supplementary Fig. 2 and Supplementary  Table 3b ). This result is significant considering that HIV clade C predominates in sub-Saharan Africa and accounts for more than 50% of all HIV infections worldwide. Interestingly, many of the clonally related monoclonal antibodies exhibited differing degrees of overall neutralization potency. For example, the median IC 50 values of PGT monoclonal antibodies 131, 136, 137 and 144 were approximately 10-to 50-fold higher than those of their somatically related sister clones ( Fig. 1 ). Also, in some cases, the somatically related monoclonal antibodies exhibited similar neutralization potency but differing degrees of neutralization breadth against the panel of viruses tested ( Fig. 1 and Supplementary Tables  3 and 4 ). For example, PGT 128 neutralized with comparable overall potency but significantly greater neutralization breadth than the clonally related PGT 125, 126 and 127 monoclonal antibodies ( Fig. 1 and Supplementary Tables 3 and 4 ). Overall, these observations suggest that serum neutralization breadth may develop from the successive selection of somatic variants that bind to a modified epitope or a slightly different Env conformation expressed on virus escape variants. Comparison of the neutralization profiles of the monoclonal antibodies isolated from a given donor with that from the corresponding serum revealed that the isolated monoclonal antibodies could largely recapitulate the serum neutralization breadth and potency ( Fig. 2 and Supplementary Fig. 3 ).
We next sought to gain information on the epitopes recognized by the newly isolated broadly neutralizing monoclonal antibodies. Enzymelinked immunosorbent (ELISA) assays indicated that PGT monoclonal antibodies 121-123, 125-128, 130, 131 and 135-137 bound to monomeric gp120 ( Supplementary Table 5 ). In contrast, the PGT 141-145 broadly neutralizing monoclonal antibodies exhibited a strong preference for membrane-bound, trimeric HIV Env ( Supplementary  Fig. 4 ). On the basis of this result, we postulated that these broadly neutralizing monoclonal antibodies bound to quaternary epitopes similar to those of the recently described PG9 and PG16 broadly neutralizing monoclonal antibodies 2 . Indeed, this hypothesis was confirmed by competition studies, N160K sensitivity and, for PGT monoclonal antibodies 141-144, an inability to neutralize JR-CSF pseudoviruses expressing homogenous Man 9 GlcNAc 2 glycans 17 ( Supplementary  Fig. 5 ).
To define the epitopes recognized by the remaining PGT antibodies, competition ELISA assays were carried out with a panel of wellcharacterized neutralizing and non-neutralizing antibodies (Fig. 3a) . Unexpectedly, all of the remaining antibodies (PGT monoclonal antibodies 121-123, 125-128, 130, 131 and 135-137) competed with the glycan-specific broadly neutralizing monoclonal antibody 2G12. This result was surprising given that 2G12 had previously formed its own unique competition group. All of the monoclonal antibodies, except for PGT monoclonal antibodies 135, 136 and 137, also 
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competed with a V3-loop-specific monoclonal antibody and failed to bind to gp120DV3, suggesting that their epitopes were in proximity to or contiguous with V3 ( Fig. 3a and Supplementary Table 5 ). Deglycosylation of gp120 with Endo H abolished binding by all the monoclonal antibodies, indicating that certain oligomannose glycans were important for epitope recognition (Supplementary Table 5 ). Competition of these monoclonal antibodies with 2G12 and lack of binding to deglycosylated gp120 prompted us to investigate whether these antibodies contacted glycans directly. Glycan array analysis revealed that PGT monoclonal antibodies 125-128 and 130 bound specifically to both Man 8 GlcNAc 2 and Man 9 GlcNAc 2 , whereas the remaining antibodies showed no detectable binding to high-mannose glycans (Fig. 3b) . Interestingly, binding of PGT monoclonal antibodies 125-128 and 130 to gp120 was competed by Man 9 but, unlike 2G12, was not competed by monomeric mannose or Man 4 (D1 arm of Man 9 GlcNAc 2 ) ( Fig. 3c, d ), suggesting a different mode of glycan recognition. Furthermore, in contrast to 2G12, no evidence was found for domain exchange and monomeric Fab fragments still exhibited potent neutralizing activity ( Supplementary Fig. 7 and data not shown).
To define further the epitopes recognized by the monoclonal antibodies, neutralizing activity against a large panel of HIV-1 JR-CSF variants incorporating single alanine substitutions was assessed using a single round of replication pseudovirus assay (Supplementary Table 6 ). In the panel of mutants, the N-linked glycans at positions 332 and/or 301 were important for neutralization by PGT monoclonal antibodies 125-128, 130 and 131, suggesting their direct involvement in epitope formation. The apparent dependency on so few glycans indicates that, although these PGT monoclonal antibodies contact Man 8-9 GlcNAc 2 glycans directly, their arrangement in the context of gp120 is critical for high-affinity glycan recognition and neutralization potency. This is further highlighted by the inability of the PGT monoclonal antibodies to neutralize simian immunodeficiency virus (SIV) strain SIV MAC239 , HIV-2 or HCV, which show a high level of glycosylation (data not shown). Interestingly, although PGT monoclonal antibodies 121-123 failed to exhibit detectable binding to high-mannose glycans and be competed by mannose sugars ( Supplementary Fig. 6 ), the only substitutions that completely abolished neutralization by these monoclonal antibodies were those that resulted in removal of the glycan at position 332. Although structural studies will be required to fully define the epitopes recognized by these antibodies, the above results indicate either that the PGT monoclonal antibodies 121-123 bind to a protein epitope along the gp120 polypeptide backbone that is conformationally dependent on the N332 glycan or that the glycan contributes more strongly to binding in the context of the intact protein.
Vaccines against pathogens with low antigenic diversity, such as hepatitis B virus or measles, commonly achieve 90-95% efficacy 18 . Similarly, the influenza vaccine achieves 85-90% efficacy in years when the vaccine and circulating seasonal strain are well matched 19, 20 . However, efficacy drops severely in years when there is a mismatch between the vaccine and circulating strain. In the case of HIV, the global diversity of circulating viruses is such that the match between the prophylactic antibodies and the circulating viruses-that is, the antibody viral coverage-will be crucial for the degree of efficacy of active or passive prophylaxis approaches. As yet, although the recent 
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RV144 trial has led to speculation that some degree of protection against HIV may be achieved through extra-neutralizing activities of antibodies, such as antibody-dependent cell-mediated cytotoxicity or phagocytosis, the strongest evidence for protection is for neutralizing antibodies in non-human primate models using simian-human immunodeficiency virus (SHIV) challenge [21] [22] [23] [24] [25] . Passive administration of neutralizing antibodies in these models suggests that a serum antibody concentration of approximately or greater than 100 times the in vitro pseudovirus assay IC 50 is required to achieve a meaningful level of protection [21] [22] [23] [24] [25] . Therefore, if a vaccine elicits a serum broadly neutralizing antibody concentration on the order of 10 mg ml 21 (ref. 26 ) and if an IC 50 :protective-serum-concentration ratio of 1:100 is assumed, then protection would be only achieved against viruses for which the broadly neutralizing antibody IC 50 is lower than 0.1 mg ml 21 . As a second more conservative scenario, for an IC 50 :protective-serum-concentration ratio of 1:500, protection would be achieved against viruses for which the broadly neutralizing antibody IC 50 is lower than 0.02 mg ml 21 . As shown in Fig. 4 , although various broadly neutralizing monoclonal antibodies show breadth at high concentrations, viral coverage often drops sharply at lower concentrations. Therefore, if elicited or delivered singly, only the most potent antibodies, such as 121 and 128, would be able to achieve a meaningful level of viral coverage, in particular at concentrations corresponding to the more conservative scenario given above. As broadly neutralizing monoclonal antibodies show different and in some cases complementary breadth, we further looked at the theoretical coverage achieved by antibody combinations. For the two IC 50 :protective-serumconcentration ratios above, a combination of PGV04 and VRC01, the two most potent CD4 binding site broadly neutralizing monoclonal antibodies, would provide protection against 29% and 2% of viruses, respectively (Fig. 4b) . In contrast, for a vaccine eliciting antibodies with high potency and favourable non-overlapping breadth, such as 128 and 145, coverage would be achieved against 63% and 40% of viruses for the two scenarios ( Fig. 4c ). Several combinations of two broadly neutralizing monoclonal antibodies, including those directed to overlapping epitopes, can yield this degree of coverage ( Supplementary Fig. 8 ). In addition, a combination of all of the broadly neutralizing monoclonal antibodies would cover 89% and 62% of viruses, correspondingly. Coverage against such a large proportion of viruses would probably have an important impact on the pandemic. An effective vaccine against HIV will probably require the elicitation of a combination of complementary potent neutralizing antibodies. The demonstration that large numbers of potent and diverse broadly neutralizing monoclonal antibodies can be isolated from several different individuals provides grounds for renewed optimism that an antibody-based vaccine may be achievable.
METHODS SUMMARY
Activated memory B-cell supernatants were screened in a high-throughput format for neutralization activity using a micro-neutralization assay, as described 2 . Heavyand light-chain variable regions were isolated from B-cell lysates of selected neutralizing hits by reverse transcription from RNA followed by multiplex PCR amplification using family-specific V-gene primer sets. For some antibodies, traditional cloning methods were used for antibody isolation, as described 2 . For other antibodies, amplicons from each lysate were uniquely tagged with multiplex identifier (MID) sequences and 454 sequencing regions (Roche). Single rounds of replication pseudovirus neutralization assays and cell surface binding assays were performed as described previously 2, 27, 28 . Glycan reactivities were profiled on a printed glycan microarray (version 5.0 from the Consortium for Functional Glycomics) as described previously 29 .
